Compare Stocks: UPC vs. AKAN vs. IXHL vs. BIOA
Compare normalized stock price performance over 6 months, 1 year or 2 years. Each line starts at 0%, so different stock prices can be compared on the same scale.
UPCAKANIXHLBIOA
Market Snapshot
Current market context for the selected companies.
UPC
$5.30
Market Cap
$3.52M
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Data through
2026-08-21
AKAN
$3.86
Market Cap
$2.09M
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Data through
2026-08-21
IXHL
$3.57
Market Cap
$42.71M
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Data through
2026-08-21
BIOA
$9.48
Market Cap
$435.10M
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Data through
2026-08-21
Performance
Absolute returns and relative performance versus SPY.
| Metric | UPC | AKAN | IXHL | BIOA |
|---|---|---|---|---|
| 1 Month | +39.8% | -52.2% | +13.0% | -56.7% |
| 1 Month vs SPY | +36.1% | -55.9% | +9.2% | -60.4% |
| 3 Months | +97.0% | -83.5% | -1.9% | -43.4% |
| 3 Months vs SPY | +93.9% | -86.6% | -5.0% | -46.5% |
| 6 Months | +81.5% | -7.9% | -57.5% | -53.8% |
| 6 Months vs SPY | +70.4% | -18.9% | -68.6% | -64.8% |
| 1 Year | +48.5% | -95.8% | -70.6% | +113.5% |
| 1 Year vs SPY | +28.5% | -115.8% | -90.6% | +93.5% |
| 2 Years | -99.8% | -98.0% | -92.3% | — |
| 2 Years vs SPY | -137.9% | -136.1% | -130.4% | — |
Growth & Profitability
Operating growth, margins and capital efficiency.
Valuation
Common valuation multiples shown side by side.
Cash Flow & Balance Sheet
Cash generation and leverage context.
Earnings Outlook
Upcoming earnings expectations when available.